Top

Published in:

01-07-2014 | Short Communication

High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with ^99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin

Authors: Oscar Arrieta, Luis-Alberto Medina, Enrique Estrada-Lobato, Laura-Alejandra Ramírez-Tirado, Víctor-Osvaldo Mendoza-García, Jaime de la Garza-Salazar

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2014

Abstract

Background

There are currently no available biomarkers for advanced pleural mesothelioma that determine which patients could benefit from a specific chemotherapy regimen.

Methods

Based on the results of a previously published phase II study, we associated the ^99mTechnetium-labelled liposomal doxorubicin (^99mTc-LD) uptake value (75 % cut-off) with the response rate, progression-free survival and overall survival of patients treated with a combination of liposomal doxorubicin and cisplatin.

Results

Patients with tumours exhibiting increased ^99mTc-LD uptake showed better response rates, progression-free survival and overall survival than those exhibiting lower uptake 73.3 versus 15 % (p < 0.001); 6.9 versus 3.2 months (p = 0.033) and 23 versus 6.6 months (p = 0.001), respectively.

Conclusion

^99mTc-DL uptake in tumour tissue could define a set of patients who would benefit from this chemotherapy regimen.

Aguilar-Madrid G, Robles-Pérez E, Juárez-Pérez CA, Alvarado-Cabrero I, Rico-Méndez FG, Javier KG (2010) Case–control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 53(3):241–251. doi:10.1002/ajim.20780 PubMed

Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M, Gulisano M, Castagneto B, Scagliotti G, Rinaldi M (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67(12):2984–2987PubMedCrossRef

Arrieta Ó, Medina LA, Estrada-Lobato E, Hernández-Pedro N, Villanueva-Rodríguez G, Martínez-Barrera L, Macedo EO, López-Rodríguez V, Motola-Kuba D, Corona-Cruz JF (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 106(6):1027–1032. doi:10.1038/bjc.2012.44 PubMedCentralPubMedCrossRef

Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G (2000) Caelyx™ in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11(6):697–700PubMedCrossRef

Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A (1998) Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114(3):713–722PubMedCrossRef

Head HW, Dodd GD 3rd, Bao A, Soundararajan A, Garcia-Rojas X, Prihoda TJ, McManus LM, Goins BA, Santoyo CA, Phillips WT (2010) Combination radiofrequency ablation and intravenous radiolabeled liposomal doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology 255(2):405–414. doi:10.1148/radiol.10090714 PubMedCentralPubMedCrossRef

Health and Safety Executive (2013) Mesothelioma in Great Britain 2013. Mesothelioma mortality in Great Britain 1968–2011. Health and Safety Executive, UK

Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11(3):118–120PubMedCrossRef

Ji S, Zheng Y, Shao G, Zhou Y, Liu S (2013) Integrin αvβ3-targeted radiotracer (99m)Tc-3P-RGD2 useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD2 therapy. Theranostics 3(11):816–830. doi:10.7150/thno.6989 PubMedCentralPubMedCrossRef

10.

Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N (2013) Excision repair cross complementation group 1 and thymidylate synthase expression in mesothelioma patients. Clin Lung Cancer 14(2):164–171. doi:10.1016/j.cllc.2012.09.003 PubMedCrossRef

11.

Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH (2012) Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30(27):3345–3352. doi:10.1200/JCO.2011.40.8120 PubMedCentralPubMedCrossRef

12.

Lee CW, Murray N, Anderson H, Rao SC, Bishop W (2009) Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3):308–313. doi:10.1016/j.lungcan.2008.09.008 PubMedCrossRef

13.

Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM (2013) Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 8(4):469–477. doi:10.1097/JTO.0b013e318283da3e PubMedCrossRef

14.

Arrieta O, López-Macías D, Mendoza-García VO, Bacon-Fonseca L, Muñoz-Montalvo W, Macedo-Pérez EO,Muñiz-Hernández S, Blake-Cerda M, Corona-Cruz JF (2014) A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 73(5):975–982. doi:10.1007/s00280-014-2429-5

15.

Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U, Tassi G, Trodella L, Zompatori M, Scagliotti G (2013) Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev 39(4):328–339. doi:10.1016/j.ctrv.2012.11.004 PubMedCrossRef

16.

Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8):3441–3444PubMed

17.

Sharif S, Zahid I, Routledge T, Scarci M (2011) Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact CardioVasc Thorac Surg 12(5):806–811. doi:10.1510/icvts.2010.255901 PubMedCrossRef

18.

Sørensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleuralmesothelioma. Br J Cancer 99(1):44–50. doi:10.1038/sj.bjc.6604421 PubMedCentralPubMedCrossRef

19.

van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G (2005) European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 28:6881–6889CrossRef

20.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644PubMedCrossRef

Title: High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin
Authors: Oscar Arrieta
Luis-Alberto Medina
Enrique Estrada-Lobato
Laura-Alejandra Ramírez-Tirado
Víctor-Osvaldo Mendoza-García
Jaime de la Garza-Salazar
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2477-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors

Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories

Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer